The Eleventh International Pharmaceutical and Medical Device Compliance Congress
LISBON MARRIOTT HOTEL, LISBON, PORTUGAL
MAY 15 – 17, 2017

CONFIRMED KEYNOTE SPEAKERS:

Nicola Bonucci, DEA, DESS, LLM, Director, Directorate for Legal Affairs, OECD, Paris, France
Tarek Helou, Esq., Assistant Chief, FCPA Unit, Fraud Section, Criminal Division, U.S. Department of Justice, Washington, DC, USA
Sophie Peresson, LLM, MSc, Global Health Policy Director, Pharmaceuticals & Healthcare Programme, Transparency International UK; Former Regional Director, International Diabetes Federation European Region; Former Communications and Advocacy Manager, European Council on Refugees and Exiles, London, UK
Marie-Claire Pickaert, Deputy Director General, Chief Financial Officer and Ambassador to the Medical Communities, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium

CONFIRMED KEYNOTE SPEAKERS:

Neill Stansbury, Esq., Co-founder and Director, Global Infrastructure Anti-Corruption Centre; Chair, International Organization for Standardization Anti-Bribery Project Committee; Vice Chair, Anti-corruption Standing Committee, World Federation of Engineering Organization, Buckinghamshire, UK
Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland
George “Ren” McEachern, CFE, CAMS, Supervisory Special Agent, International Corruption Squad, US Federal Bureau of Investigation, Washington, DC, USA
Aleksandar Rusanov, Esq., Legal Advisor, Legal Department, European Medicines Agency (EMA), London, UK

CONFIRMED KEYNOTE SPEAKERS:

Sujata Dayal, JD, Vice President, Health Care Compliance and Privacy, Global Chief Compliance Officer, Pharmaceuticals, Johnson and Johnson; Former Chief Compliance Officer and Corporate Vice President, Biomet, Inc.; Former Ethics and Compliance Officer, Abbott Laboratories, Titusville, NJ, USA
Lori V. Queisser, CPA, Senior Vice President and Global Compliance Officer, Teva Pharmaceuticals, Philadelphia, PA, USA
Uffe Kåre Rasmussen, M.Sc., Senior Director and Chief Compliance Officer, H. Lundbeck A/S; Former Principal Scientist, Novo Nordisk A/S, Copenhagen, Denmark

CONFIRMED KEYNOTE SPEAKERS:

Continuing Education Credits:

Accounting Professionals: Approved for up to 17.0 NASBA CPE credits.
Attorneys: Pending approval for PA MCLE credits.

CONFIRMED KEYNOTE SPEAKERS:

COMPLIANCE PROFESSIONALS: Pending approval for Compliance Certification Board CCB credits.

CONFIRMED KEYNOTE SPEAKERS:

CONGRESS CO-CHAIRS:

Dante Beccaria, Senior Vice President, Global Head of Ethics and Business Integrity, Sanofi, Paris, France
Stephen Nguyen Duc, Office of Ethics & Compliance Area Director, International Operations, Western Europe & Canada, AbbVie; Board Member, Strategic Committee International Society of Healthcare, Ethics, and Compliance Professionals (ETHICS), Rungis, France
Dominique Laymand, Esq., Senior Vice President, Chief Ethics and Compliance Officer, Ipsen; President, International Society of Healthcare Ethics and Compliance Professionals (ETHICS), Paris, France
Roeland Van Aelst, Regional Vice President - HCCO M&D EMEA & Canada, Office Health Care Compliance and Privacy, Johnson & Johnson; Co-chair, Strategic Committee, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS); Chairman, MedTech Compliance Network, Brussels, Belgium

CONFIRMED KEYNOTE SPEAKERS:

Offered in Sequence with an EFPIA Stakeholder Workshop:
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is offering an independent EFPIA STAKEHOLDER WORKSHOP on Monday, May 15, 2017.
The First International Pharmaceutical Compliance Congress and Best Practices Forum was held in June 2007 to bring together company compliance professionals, regulators, lawyers, and consultants working in this interesting and expanding field. The purpose was to hold a truly global conference, addressing the key issues of the day. The first international conference agenda was developed with inputs from company compliance professionals around the topics they wanted to know more about, which continues to be one of the great strengths of these conferences. The 2017 Co-Chairs and Planning Committee have designed the Congress around the themes of anti-corruption/anti-bribery compliance programs, data privacy, new marketplace, transparency, and the next generation of ethics and compliance programs.

The Congress this year features Keynote Plenary Session speakers from important organizations including the European Medicines Agency (EMA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the International Organization for Standardization Anti-Bribery Project Committee (ISO 37001), the Organisation for Economic Co-operation and Development (OECD), Transparency International, the United States Department of Justice FCPA Unit and the United States Federal Bureau of Investigations International Corruption Squad. The Mini Summit panels include experts working within the pharmaceutical and medical device companies as well as legal counsel and consultants who will discuss the practical implementation of compliance control measures.


WHO SHOULD ATTEND:
- Pharmaceutical Manufacturers
- Generic Pharmaceutical Manufacturers
- Medical Device Manufacturers
- Site Management Organizations
- Clinical Research Organizations
- Management Companies
- Wholesale, Retail, Mail Order and Internet Pharmacies
- Health Care Regulators and Policy Makers
- Pharmaceutical and Health Care Executives and Board Members
- Regulatory and Compliance Professionals
- Medical Directors
- Physicians and Other Health Care Professionals
- Pharmacists
- Food and Drug Law Attorneys
- Health Care Attorneys and In-house Counsel
- Compliance Officers
- Privacy Officers
- Ethics Officers and Corporate Social Responsibility Personnel
- Pharmaceutical Consultants
- Investment Bankers
- Venture Capitalists
- Health Services Researchers and Academics
- Auditors
- Promotion Signatories/Approvers
- Risk Management Personnel
- Governmental Policy Makers and Regulators

SPONSOR:

INTERNATIONAL SOCIETY OF HEALTHCARE ETHICS AND COMPLIANCE PROFESSIONALS (ETHICS) is a new professional Society established in 2012 currently comprised of around 50 members, all active in major pharma and medical device companies. ETHICS intends to become the reference professional society for ethics and compliance practitioners in the healthcare sector with the ultimate goal to contributing to the professional development of individuals and the success of ethics and compliance organizations.

CO-SPONSOR:

THE PHARMACEUTICAL COMPLIANCE FORUM (PCF) is a coalition of senior compliance professionals and legal counsel from more than 60 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field, and sponsors a three-day compliance congress each Fall.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is offering an independent session on Monday, May 15, 2017 from 9:00 am to 12:00 pm.

The session will address the role of self-regulation against the background of applicable laws and regulations, and how global ethical principles translate into the variety of local standards, rules, and procedures in Europe. The session also will discuss the evolution of norms, often following practice, and self-regulation anticipating evolution of new approaches and practices.

12:00 pm Adjournment

MONDAY, MAY 15, 2017

INTERNATIONAL PHARMA CONGRESS DAY I: OPENING PLENARY SESSION

1:00 pm Welcome to Lisbon from APIFARMA

Heitor Costa, Executive Director, Portuguese Association of the Pharmaceutical Industry (APIFARMA), Lisbon, Portugal

1:10 pm CONGRESS CO-CHAIR WELCOME AND OVERVIEW

Dante Beccaria, Senior Vice President, Global Head of Ethics and Business Integrity, Sanofi, Paris, France (Co-chair)

Dominique Laymand, Esq., Senior Vice President, Chief Ethics and Compliance Officer, Ipsen; President, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS), Paris, France (Co-chair)

Stephen Nguyen-Duc, Area Director Ethics & Compliance Western, Europe-Israel and Canada, AbbVie; Former Director, Ethics & Compliance Officer, Eli Lilly and Company, Paris, France (Co-chair)

Roeland Van Aelst, Regional Vice President - HCCO MDD&D EMEA & Canada, Office Health Care Compliance and Privacy, Johnson & Johnson; Board Member, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS), Chairman, MedTech Compliance Network, Brussels, Belgium (Co-chair)

1:30 pm Chief Compliance Officer Roundtable: Key Risks for the Industry and the Future of Ethics and Compliance Programs

Dante Beccaria, Senior Vice President, Global Head of Ethics and Business Integrity, Sanofi, Paris, France

Sujata Dayal, JD, Vice President, Health Care Compliance and Privacy, Global Chief Compliance Officer, Pharmaceuticals, Johnson and Johnson; Former Chief Compliance Officer and Corporate Vice President, Biomet, Inc.; Former Ethics and Compliance Officer, Abbott Laboratories, Titusville, NJ, USA

Dominique Laymand, Esq., Senior Vice President, Chief Ethics and Compliance Officer, Ipsen; President, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS), Paris, France

3:45 pm Networking Break

MINI SUMMITS ROUND I

MS 1: Transparency: Now that We Have the Data, How Can We Leverage It to Improve Compliance?

4:15 pm Introductions, Discussion and Q&A

Anna Byrom, LLM, Associate Director, Compliance EUCA, Intercept Pharmaceuticals; Former Associate Director, Astellas Pharma Europe, London, UK

Filipa Godinho, Business Consultant, Global Transparency, Eli Lilly and Company, Lisbon, Portugal

Fabien Roy, DESS, Former Associate Director, Astellas Pharma Europe, London, UK

George Fife, Executive Director, Fraud Investigation & Dispute Services, EY; Former Executive Director, Compliance & Ethics, Bristol-Myers Squibb, Paris, France (Moderator)

MS 2: Annual MEA Compliance Roundtable

4:15 pm Introductions, Discussion and Q&A

Mostafa Abdelrahman, Ethics and Compliance Director, Eli Lilly and Company, Riyadh, Kingdom of Saudi Arabia

Rifat Bozacioglu, Area Compliance Director, Middle East, GlaxoSmithKline plc, Istanbul, Turkey

Laura Nassar, Head of Compliance, Middle East, Roche Pharmaceuticals, Dubai, United Arab Emirates

Dream Samir, Consultant, AMICULUM-ME, Secretary General, Pharmaceutical Research and Manufacturers Association, Gulf (PHIMAG), Dubai, United Arab Emirates

Maged Zaki, MD (Invited), Health Care Business Integrity Officer, Pharma GCC Cluster, Middle East, West Asia and Africa, Johnson and Johnson, Dubai, United Arab Emirates

Joe Henein, Pharm.D., President and Chief Executive Officer, NewBridge Pharmaceuticals FZ LLC, Dubai, United Arab Emirates (Moderator)
MS 3: Health Economics and Outcomes Research (HEOR)—Emerging Risks of Data Collection, Use, and Secondary Use
4:15 pm   Introductions, Discussion and Q&A
Peter W.L. Bogaert, MA, LJ, Partner, Covington & Burling LLP, Brussels, Belgium
Bella Rafael Hovhannisyan, Compliance and Ethics Lead, Spain, Portugal, and Nordic Region, Bristol-Myers Squibb, Madrid, Spain
Pascale Paimbault (Invited), Executive Director, EMEA Ethics and Compliance, ABAC, Astellas Pharma Europe; Former Compliance Officer, France - Benelux, Biogen, Treasurer and Strategic Committee Member, ETHICS; Former Chief Compliance Officer EMEA, Wright Medical Inc.; Former Senior Director, Compliance and Ethics, Business Program, EMEA, Bristol-Myers Squibb, Paris, France
Ken Walsh, MA, MSc, Director, Life Sciences Consulting, Navigant, London, UK
Ann Beasley, JD, Director, Healthcare and Life Sciences Disputes, Compliance and Investigations, Navigant Consulting; Former Chief Compliance Officer, Biogen; Former Global Compliance Officer, Novartis, Boston, MA, USA (Moderator)

MS 4: Evolving Privacy Requirements: Preparing for the General Data Protection Regulation
4:15 pm   Introductions, Discussion and Q&A
Martin Fuerle, MBA, General Counsel and Chief Compliance Officer, Vice President Risk & Compliance, Daiichi Sankyo Europe GmbH, Munich, Germany
William Long, LLB, Partner, Sidley Austin LLP, London, UK
Audrey Mills, JD, Sr. Director Ethics and Compliance and Chief Privacy Officer, Eli Lilly and Company, Indianapolis, IN, USA (Moderator)

MS 5: Managing Medical Device Anti-Corruption Risks
4:15 pm   Introductions, Discussion and Q&A
Anne-Sophie Bricca, Deputy General Counsel, Senior Director Law and Compliance, EMEA, Terumo BCT, Brussels, Belgium
Ariadna Quesada, MPP, Compliance Manager Europe, Middle-East and Africa, MicroPort Orthopedics Inc., Amsterdam, Netherlands
Michele Tagliaferri, Esq., Partner, Sidley Austin LLP, Brussels, Belgium
Andy Bender, MS, MBA, President and Founder, Polaris, New York, NY, USA (Moderator)

5:30 pm   Adjournment and Networking Reception

TUESDAY, MAY 16, 2017
DAY II: MORNING PLENARY SESSION

7:30 am   Registration Commences
8:00 am   Welcome and Overview
Dante Beccaria, Senior Vice President, Global Head of Ethics and Business Integrity, Sanofi, Paris, France (Co-chair)
8:10 am   OECD Update
Nicola Bonucci, DEA, DESS, LLM, Director, Directorate for Legal Affairs, Organisation for Economic Co-operation and Development, Paris, France
8:40 AM   Transparency International Update
Sophie Peresson, MA, Global Health Policy Director, Pharmaceuticals and Healthcare, Transparency International; Former Regional Director; International Diabetes Federation, European Region; Former Senior Policy Advisor, Standing Committee of European Doctors, London, UK
9:10 am   The ISO Anti-Corruption Standard (ISO 37001)
Neill Stansbury, Esq., Co-founder and Director of the Global Infrastructure Anti-Corruption Centre; Chair, International Organization for Standardization Anti-Bribery Project Committee; Vice Chair, Anti-corruption Standing Committee, World Federation of Engineering Organization, Buckinghamshire, UK
9:40 am   Anti-Corruption Enforcement Panel
Peter Dieners, Esq., Partner and Head, Global Healthcare and Life Sciences Group, Clifford Chance, Co-chair, Legal Affairs Focus Group (LA FG), EUCOMED, Co-chair, Compliance Network (CN), EUCOMED, Düsseldorf, Germany
Ulf H. Grundmann, Esq., Partner, Life Sciences Practice Group, King & Spalding LLP, Frankfurt am Main, Germany
Michael K. Loucks, Esq., Partner, Skadden Arps LLP; Former Acting United States Attorney, District of Massachusetts, US Department of Justice, Washington, DC, USA
Paul J. Melling, Esq., Founding Partner, Baker & McKenzie - CIS, Limited, Moscow, Russia
Vivian Robinson, Esq., Queen’s Counsel, Partner, McGuire Woods; Former General Counsel of the UK Serious Fraud Office; Former Head, QEB Hollis Whiteman Chambers, Recorder of the Crown Court and Treasurer of Inner Temple, London, UK
Yuet Ming Tham, JD, Partner, Sidley Austin LLP; Former Asia Pacific Regional Compliance Director, Pfizer; Former Asia Pacific Regional Senior Counsel, Office of Inspector General, US Department of Health and Human Services, New York, NY, USA and Paris, France (Moderator)
10:45 am   Networking Break

EXHIBIT AND SPONSORSHIP OPPORTUNITIES
Take advantage of this unique opportunity to expand your reach! The Congress is attended by highly influential and experienced professionals.
Sponsorship offers you strategic positioning as an industry leader. For more information call 206-673-4815 or email exhibits@hcconferences.com.

Ted Acosta, Esq., Americas Vice Chair, Risk Management, EY; Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services, New York, NY, USA and Paris, France (Moderator)
MINI SUMMITS ROUND II 11:15 am – 12:30 pm

MS 6: Practical Implications of Brexit on Life Science Companies
11:15 am Introductions, Panel Discussion and Q&A
Janet Kidd, Esq., Vice President, EMEA, Aegerion Pharmaceuticals, Windsor, UK
Elisabethann Wright, Esq., Partner, Hogan Lovells International LLP, Brussels, Belgium (Moderator)

MS 7: The Interfaces Between the Roles of the Compliance and Quality Functions
11:15 am Introductions, Panel Discussion and Q&A
David O’Shaughnessy, Vice President, Compliance, Emerging Markets, Quintiles; Board Member, ETHICS; Former Vice President Compliance, International Pharmaceuticals, GSK; Former Vice President, Global Compliance Strategy, AstaZeneeca, Reading, UK
Fabien Roy, DESS, Senior Associate, Hogan Lovells; Member, EFGCP-MedTech Europe Working Party, Brussels, Belgium
Rajiv Joshi, ICAI, ISACA, CIA, CFE, Partner, Fraud Investigation & Dispute Services, EY, Mumbai, India (Moderator)

MS 8: Risk Assessments and Monitoring Plans, Part I
11:15 am Introductions, Panel Discussion and Q&A
Jose Manuel Garcelan, Global Compliance Consultant, Chemo; Former Regional Compliance and Privacy Officer, Merck, Sharp, and Dohme, Madrid, Spain
Michael Alan Gleave, Compliance Officer, Corporate Compliance and CSR, H. Lundbeck A/S, Copenhagen, Denmark
Anita K. Kim-Reinartz, Partner, Fraud Investigation & Dispute Services, EY, Düsseldorf, Germany
Maria-Teresa Rico Pérez, MD, Europe and Canada Regional Compliance Officer, Biogen, Zug, Switzerland
Abdul Luweshi, MBA, Executive Director, Global Operations, Ethics & Compliance, Astellas Pharma EMEA; Former Vice President, Health Care Compliance, Johnson & Johnson; Former Co-chair, Asia Pacific Pharma Compliance Congress, Chertsey, UK (Moderator)

MS 9: Patient Programs and Interactions with Patient Organizations—Managing the Risks of Getting Closer to the Patient
11:15 am Introductions, Panel Discussion and Q&A
Dominik Geller, Head Pharma Healthcare Compliance Office, Roche, Basel, Switzerland
Cécile Gousset, Associate Vice President, Compliance Risk Assessment, Education and Monitoring, Global Ethics & Business Integrity, Sanofi, Paris, France
Chris J. Holmes, Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant, London, UK
Casey Horton, Director, Healthcare and Life Sciences Disputes, Regulatory Compliance and Investigations, Navigant, Chicago, IL, USA
Tamara Tubin, LL.M, Compliance Director EU CAN, Takeda Pharmaceuticals International AG; Strategic Committee, International Society of Healthcare Ethics and Compliance Professionals (ETHICS); Former Corporate Compliance Director, Biogen International; Former Ethics and Compliance Director International, Carefusion, Zurich, Switzerland
Martin Fuere, MBA, General Counsel and Chief Compliance Officer, Vice President Risk and Compliance, Daiichi Sankyo Europe GmbH, Munich, Germany
Keith M. Korenchuk, JD, MPH, Partner, Arnold & Porter LLP, Washington, DC, USA
Roeland Van Aelst, Regional Vice President EMEA – HC CO MD&D EMEA & Canada, Office Health Care Compliance and Privacy, Johnson and Johnson; Board Member, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS); Chairman, MedTech Compliance Network, Brussels, Belgium
Frank Wartenberg, PhD, President, Central Europe, IMS Health, Frankfurt/Main, Germany
Michael Bartke, PhD, Former Director Compliance Management, DAIICHI SANKYO EUROPE GmbH, Munich, Germany (Moderator)

4:00 PM Networking Break

DAY II: AFTERNOON PLENARY SESSION

1:40 pm Welcome and Overview
Stephen Nguyen-Duc, Area Director Ethics & Compliance Western, Europe-Israel and Canada, AbbVie; Former Director, Ethics & Compliance Officer, Eli Lilly and Company, Paris, France (Co-chair)

1:45 pm Overview of the New Marketplace in 2017 and Beyond
Frank Wartenberg, PhD, President, Central Europe, IMS Health, Frankfurt/Main, Germany

2:45 pm Panel Discussion of the Challenges of the New Marketplace
• Market Access
• Demonstrating the Value of Innovation and Value-Based Payment Structures
• The Future of Biosimilars
• Targeting Treatment with Companion Diagnostics
• Health Technology Assessments
• Role of the Compliance Function

MINI SUMMITS ROUND III 4:30 pm – 5:30 pm

MS 11: Next Generation Compliance: Fostering Decision-Making in a Principle-Based Compliance Program
4:30 pm Introductions, Panel Discussion and Q&A
Timothy Ayers, JD, MPH, Vice President, Chief Compliance Officer, Horizon Pharma PLC; Former Vice President, Chief Compliance Officer, Dendreon; Former Associate General Counsel, Executive Director of Compliance, Seattle Genetics Chicago, IL, USA
Maureen McGirr, JD, Vice President, Office of Ethics, Global Compliance Organization, Merck, Sharp, and Dohme, Kenilworth, NJ, USA
Jeffrey Ayers, JD, MPH, Senior Director and Chief Compliance Officer, H. Lundbeck A/S, Former Principal Scientist, Novo Nordisk A/S, Copenhagen, Denmark
Kirtis Kraeuter, MGA, Head, Worldwide Compliance Committee and Monitoring Center of Expertise, Bristol-Myers Squibb, Princeton, NJ, USA (Moderator)

12:30 pm Networking Luncheon
**MS 12: Risk Assessment and Monitoring Plans, Part II**
4:30 pm  Introductions, Panel Discussion and Q&A
Sue Egan, Director and Principal Consultant, Sue Egan Associates; Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK
Carl Judge, Partner, Fraud Investigation & Dispute Services, EY, London, UK
Gabriela Radu, Compliance Lead & Data Privacy Officer at Amgen Romania; Former Ethics and Compliance Associate, Eli Lilly and Company, Bucharest, Romania
Jolanta Wyszynska, Vice President, Compliance Europe, AstraZeneca, Warsaw, Poland
Abdul Luheshi, MBA, Executive Director, Global Operations, Ethics & Compliance, Astellas Pharma EMEA; Former Vice President, Health Care Compliance, Johnson & Johnson; Former Co-chair, Asia Pacific Pharma Compliance Congress, Chertsey, UK (Moderator)

**MS 13: The Challenges of New Channels: Digital Communications, Social Media, and Other New Technologies**
4:30 pm  Introductions, Panel Discussion and Q&A
Grant Castle, Esq., Partner, Covington & Burling LLP, London, UK
Giota Papamarkou, Global Ethics & Compliance Director, Ipsen; Former EMEA Compliance and Ethics Manager, Bristol-Myers Squibb, Paris, France
Melda Tanyeri, MS, MBA, Director, Fraud Investigation & Dispute Services, EY, London, UK (Moderator)

**MS 14: Advanced Topics in Anti-Corruption Compliance Programs**
4:30 pm  Introductions, Panel Discussion and Q&A
Keith M. Korenchuk, JD, MPH, Partner, Arnold & Porter LLP, Washington, DC, USA
Michael O’Connor, Senior Director, Global Head Ethics and Compliance Operations, Alexion Pharmaceuticals, Inc., Cheshire, CT, USA
Daniel Schafaghi, Global Compliance Operating Officer, Head of Compliance Emerging Markets, Boehringer Ingelheim GmbH, Ingelheim, Germany
Geert van Gansewinkel, Managing Partner, Europe and Asia Pacific, Polaris, Amsterdam, Netherlands (Moderator)

**MS 15: Impact of Self-Regulation Schemes on Industry Relationships with HCPs, HCOs and Patient Organizations**
4:30 pm  Introductions, Panel Discussion and Q&A
Holger Diener, PhD, Managing Director, Association of Voluntary Self-Regulation for the Pharmaceutical Industry; Vice-Chair, Ethics and Business Integrity Committee (eBIC), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Berlin, Germany
Jose F. Zamarriego Izquierdo, PhD, Director Unidad de Supervision Deontologica, Farmaindustria, Madrid, Spain
Jose Ramos, MBA, Compliance Officer for Italy, Portugal, and Spain, Biogen, Madrid, Spain
Heather Simmonds, Director, Prescription Medicines Code of Practice Authority, London, UK
Brian Sharkey, JD, Vice President, Porzio Life Sciences, LLC, Morristown, NJ, USA (Moderator)

5:45 pm  Adjournment

**HOTEL INFORMATION/RESERVATIONS**
The Marriott Lisbon is the official hotel for the International Pharmaceutical Compliance Congress. A special group rate of €165.00 per night including breakfast and wi-fi has been arranged. To make reservations online, please visit [www.internationalpharmacongress.com](http://www.internationalpharmacongress.com) and go to the travel/hotel link. Reservations at the group rate will be accepted until April 21, 2017. After this date, reservations will be accepted on a space-available basis at the prevailing rate.

The International Pharmaceutical and Compliance Congress does not contract with any third party organization to make hotel reservations for attendees of the Congress. All attendees should make their hotel reservations directly with the hotel and not with a third party vendor.

**Lisbon Marriott Hotel**
Avenida dos Combatentes, 45, 1600-042 • Lisbon, Portugal
+351 21 723 5400
DAY III: CLOSING PLENARY SESSION

8:30 am  Welcome and Introduction
Roeland Van Aelst, Regional Vice President - HCCO MD&D EMEA & Canada, Office Health Care Compliance and Privacy, Johnson & Johnson; Board Member, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS); Chairman, MedTech Compliance Network, Brussels, Belgium (Co-chair)

8:40 am  IFPMA Keynote Speech
Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland

9:10 am  Clinical Data Transparency: The EMA Experience
Aleksandar Rusanov, Esq., Legal Advisor, Legal Department, European Medicines Agency (EMA), London, UK

9:40 am  Panel Discussion on Data Privacy
Aleksandar Rusanov, Esq., Legal Advisor, Legal Department, European Medicines Agency (EMA), London, UK

Elisabethann Wright, Esq., Partner, Hogan Lovells International LLP, Brussels, Belgium

David Andersen, Partner, Pharmaceuticals and Life Sciences, PwC, London, UK (Moderator)

10:45 am  Networking Break

11:15 am  EFPIA Keynote Speech
Marie-Claire Pickaert, Deputy Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium

11:45 am  Current Initiatives of the Trade Associations
APIFARMA
Pedro Caridade de Freitas, LLM, PhD, Legal and Compliance Director, Portuguese Association of the Pharmaceutical Industry (APIFARMA), Lisbon, Portugal

EFPIA
Marie-Claire Pickaert, Deputy Director General, European Federation of Pharmaceutical Industries and Associations, (EFPIA), Brussels, Belgium

EUCOMED AND EMA CODE
Roeland Van Aelst, Regional Vice President - HCCO MD&D EMEA & Canada, Office Health Care Compliance and Privacy, Johnson & Johnson; Board Member, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS); Chairman, MedTech Compliance Network, Brussels, Belgium

IFPMA
Sofie Melis, Senior Manager, Ethics and Compliance, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland

MEA
Dream Samir, Consultant, AMICULUM-ME, Secretary General, Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG), Dubai, United Arab Emirates

Oscar Perdomo, Director, Pharmaceuticals and Life Sciences, PwC, Switzerland (Moderator)

1:00 pm  Adjournment
### 2017 INTERNATIONAL PHARMA CONGRESS PLANNING COMMITTEE

**CO-CHAIRS**

Dante Beccaria, Global Compliance Officer and Vice President, Sanofi; Former Vice President of Internal Audit, Sanofi, Paris, France

Stephen Nguyen Duc, Office of Ethics & Compliance Area Director, International Operations, Western Europe & Canada, AbbVie; Board Member, Strategic Committee International Society of Healthcare, Ethics, and Compliance Professionals (ETHICS), Rungis, France

Dominique Laymand, Esq., Senior Vice President, Chief Ethics and Compliance Officer, Ipsen; President, International Society of Healthcare Ethics and Compliance Professionals (ETHICS), Paris, France

Roeland Van Aelst, Regional Vice President - HCO MBD BMEA & Canada, Office Health Care Compliance and Privacy, Johnson & Johnson; Co-chair, Strategic Committee, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS); Chairman, MedTech Compliance Network, Brussels, Belgium

**MEMBERS**

Timothy Ayers, JD, MPH, Vice President, Chief Compliance Officer, Horizon Pharma PLC; Former Vice President, Chief Compliance Officer, Dendreon; Former Associate General Counsel; Executive Director of Compliance, Seattle Genetics, Chicago, IL, USA

Michael Bartke, PhD, Former Director Compliance Management, DAICHI SANKYO EUROPE GmbH, Munich, Germany

Ann Beasley, JD, Director, Healthcare and Life Sciences Disputes, Compliance & Investigations, Navigant Consulting; Former Chief Compliance Officer, Biogen; Former Global Compliance Officer, Novartis, Boston, MA, USA

Andy Bender, MS, MBA, President and Founder, Polaris, New York, NY, USA

Leonardo Cassara A. Silva, LLM, Global Compliance Officer, Ferring International Center S.A.; Former Head of Compliance, Acino Pharma AG; Former Compliance Director, Emerging Markets, Takeda Pharmaceuticals, Saint-Prem, Switzerland

Sujata Dayal, Vice President, Health Care Compliance and Privacy, Global Chief Compliance Officer, Pharmaceuticals, Johnson & Johnson; Former Chief Compliance Officer and Corporate Vice President, Biomet, Inc.; Former Ethics and Compliance Officer, Abbott Laboratories, Titusville, NJ, USA

Sue Egan, Director and Principal Consultant, Sue Egan Associates; Former Vice President, Compliance, AstraZeneca; Great Missenden, Buckinghamshire, UK

Martin Fuerle, MBA, General Counsel and Chief Compliance Officer, Vice President Risk & Compliance, Daiichi Sankyo Europe GmbH, Munich, Germany

Gary F. Giampetruzzi, Esq., Partner, Paul Hastings; Former Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc., New York, NY, USA

Ulf H. Grundmann, Esq., Partner, King and Spalding, Frankfurt am Main, Germany

Kirtis Kraeuter, MGA, Head, Worldwide Compliance Committee and Monitoring Center of Expertise, Bristol-Myers Squibb, Princeton, NJ, USA

Evelyne Lemaire, Head of Compliance, Europe & Canada, Takeda Pharmaceuticals International GmbH; Former Director, Global Pharmaceutical and Life Sciences, PwC LLP, Zurich, Switzerland

Maureen McGirr, JD, Vice President, Office of Ethics, Global Compliance Organization, Merck, Sharp, and Dohme, Kenilworth, NJ, USA

Paul J. Meling, Esq., Founding Partner, Baker & McKenzie-CIS, Limited, Moscow, Russia

Laura Nassar, Head of Compliance, Middle East, Roche Pharmaceuticals, Dubai, UAE

John Patrick Oroho, Esq., Executive Vice President and Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio, Bromberg & Newman PC, Morristown, NJ, USA

David O’Shaughnessy, Vice President, Compliance, Emerging Markets, Quintiles; Board Member, ETHICS; Former Vice President Compliance, International Pharmaceuticals, GSK; Former Vice President, Global Compliance Strategy, AstraZeneca, Reading, UK

Maria-Teresa Rico Pérez, MD, Europe and Canada Regional Compliance Officer, Biogen, Zug, Switzerland

Marie-Claire Pickaert, MA, Deputy Director General, Chief Financial Officer and Ambassador to the Medical Communities, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium

Ariadna Quesada, MPP, Compliance Manager Europe, Middle-East and Africa, MicroPort Orthopedics Inc., Amsterdam, Netherlands

Uffe Kåre Rasmussen, MSc, Senior Director and Chief Compliance Officer, H. Lundbeck A/S; Former Principal Scientist, Novo Nordisk A/S, Copenhagen, Denmark

Vivian Robinson, Esq., Queen’s Counsel, Partner, McGuire Woods, London, UK

Hubertus Stockmann, MBA, Divisional Compliance Officer, Merck KgA, Frankfurt, Germany

Mariusz Witalis, Partner, Fraud Investigation and Dispute Services, Ernst & Young LLP, Warsaw, Poland

Elisabethann Wright, Esq., Partner, Hogan Lovells International LLP, Brussels, Belgium

Jolanta Wyszynska, Vice President, Compliance Europe, AstraZeneca, Warsaw, Poland

Jose F. Zamarriego Izquierdo, Director Unidad de Supervision Deontologica, Farmaindustria, Madrid, Spain

### 2017 GLOBAL PHARMA COMPLIANCE CONGRESSES

- **Washington, DC**
  - June 26 – 28
  - November 4 – 8

- **Lisbon**
  - May 15 – 17

- **Mumbai**
  - November 14 – 16

- **Shanghai**
  - September 13 – 15
Save these Dates in 2017!

NATIONAL MEDICAL AFFAIRS COMPLIANCE SUMMIT
The Leading Forum on Compliance Issues Related to Medical Affairs Activities of Pharmaceutical and Medical Device Companies • A Hybrid Conference and Internet Event
Offered in Sequence with the Second Pharma Managed Markets Compliance Summit
Media Partners: Harvard Health Policy Review, Health Affairs and Life Sciences Compliance Update
June 26 – 27, 2017, Hyatt Regency Crystal City, Washington, DC
www.MedicalAffairsSummit.com

SECOND PHARMACEUTICAL SUMMIT ON BUSINESS AND COMPLIANCE ISSUES IN MANAGED MARKETS
The Leading Forum on Pharmaceutical Market Access, Reimbursement, Pricing, and Contracting with Commercial and Government Payers • A Hybrid Conference and Internet Event
Offered in Sequence with the National Medical Affairs Compliance Summit
Media Partners: Harvard Health Policy Review, Health Affairs and Life Sciences Compliance Update
June 27 – 28, 2017, Hyatt Regency Crystal City, Washington, DC
www.PharmaManagedMarketsSummit.com

SEVENTH ASIA PACIFIC PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS
Sponsored by Asia Pacific Healthcare Industry Compliance Team
Cosponsored by International Society of Healthcare Ethics and Compliance Professionals (ETHICS) and Pharmaceutical Compliance Forum (PCF)
Media Partner: Life Sciences Compliance Update
September 13 – 15, 2017, InterContinental Shanghai, Shanghai, China
www.AsianPharmaCongress.com

EIGHTEENTH ANNUAL PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS
Transformational Learning – Effective Knowledge Exchange • A Hybrid Conference and Internet Event
Sponsored by Pharmaceutical Compliance Forum
Media Partners: Harvard Health Policy Review, Health Affairs and Life Sciences Compliance Update
November 6 – 8, 2017, Mandarin Oriental, Washington, DC • www.PharmaCongress.com

INDIAN PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS (TENTATIVE)
Cosponsored by International Society of Healthcare Compliance Professionals (ETHICS) and Pharmaceutical Compliance Forum (PCF)
Media Partner: Life Sciences Compliance Update
November 14 – 16, 2017, Mumbai, India • www.IndianPharmaCongress.com
THE FOLLOWING REGISTRATION TERMS AND CONDITIONS APPLY

PAYMENTS
All payments must be made in Euros. Payments are only accepted through credit card and bank transfer. A person will not be deemed to be formally registered until payment in full has been received. To receive the early bird discount, payment must be received by the early bird date. All payments must be made within 10 days of registration in order to reserve your seat at the conference. Delegates with outstanding payment balances will be asked for payment on site, proof of payment or a guarantee by credit card. Seating will be subject to availability.

PRO FORMA INVOICES
Complete one of the online forms and generate a Pro Forma Invoice, or fill out the downloadable form to email, fax, or mail in your request for a Pro Forma Invoice. For questions about the registration process, contact the Registration Office at 1-800-503-8171 and 1-206-452-5528, or send an email to registration@hcconferences.com.

REGARDING ONSITE REGISTRATION, CANCELLATIONS AND SUBSTITUTIONS
1. For onsite group registrations, full registration and credit card information is required for each registrant. List all members of groups registering concurrently on fax or scanned cover sheet.
2. For onsite registrants there will be no refunds for “no-shows” or for cancellations. You may send a substitute. Please call the Conference Office at 1-800-503-8171 or 1-206-452-5528 for further information.

METHOD OF PAYMENT FOR TUITION
Make payment to Health Care Conference Administrators LLC by Mastercard, Visa or American Express. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC.

REGISTRATION OPTIONS
Registration may be made online or via mail, fax or scan. You may register through either of the following:
• Fax/Mail/Email using this printed registration form. Mail the completed form with payment to the Conference registrar at 12330 N.E. 8th Street, Suite 101, Bellevue, WA 98005-3187, USA, or fax the completed form to 1-206-319-5303, or scan and email the completed form to registration@hcconferences.com.

The following credit cards are accepted: American Express, Visa or MasterCard. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC.

For registrants awaiting company bank transfer, a credit card number must be given to hold registration. If payment is not received by seven days prior to the Congress, credit card payment will be processed.

TAX DEDUCTIBILITY
Expenses of training including tuition, travel, lodging and meals, incurred to maintain or improve skills in your profession may be tax deductible. Consult your tax advisor. Federal Tax ID: 91-1892021.

CANCELLATIONS/SUBSTITUTIONS
No refunds will be given for “no-shows” or for cancellations. You may send a substitute. Please call the Conference Office at 1-800-503-8171 and 1-206-452-5528, or send an email to registration@hcconferences.com.

INTELLECTUAL PROPERTY POLICY
Unauthorized sharing of Congress content via Webcast access through the sharing of user names and passwords or via alternative media (Flash Drive) through the sharing of said media is restricted by law and may subject the copyright infringer to substantial civil damages. The Congress aggressively pursues copyright infringers. If a registrant needs the ability to share Congress content within his or her organization, multiple Congress registrations are available at discounted rates.

The Congress will pay a reward for information regarding unauthorized sharing of Congress content. The reward will be one quarter (25%) of any recovery resulting from a copyright infringement (less legal fees and other expenses related to the recovery) up to a maximum reward payment of $25,000. The payment will be made to the individual or individuals who in the opinion of our legal counsel first provided the factual information, which was necessary for the recovery. If you have knowledge regarding the unauthorized Congress content sharing, contact the Congress registration office.

REGISTRATION BINDING AGREEMENT
Registration (whether online or by this form) constitutes a contract and all of these terms and conditions are binding on the parties. In particular, these terms and conditions shall apply in the case of any credit card dispute.

GENERAL TERMS AND CONDITIONS
Program subject to cancellation or change. If the program is cancelled the only liability of the Congress will be to refund the registration fee paid. The Congress shall have no liability regarding travel or other costs. Registration form submitted via fax, mail, email or online constitutes binding agreement between the parties.

FOR FURTHER INFORMATION
Call 1-800-503-8171 (Continental US, Alaska and Hawaii only) or 1-206-452-5528, send e-mail to registration@hcconferences.com, or visit our website at www.InternationalPharmaCongress.com.

VISA INFORMATION
Travelers to Portugal from the United States, Canada and most European countries do not require a Visa. For specific information regarding your country of origin visit the Portuguese Consulate Website or https://visahq.com/.
INTERNATIONAL PHARMA CONGRESS

HOW TO REGISTER: Fully complete the form on page 11 (one form per registrant, photocopies acceptable). Payment must accompany each registration (Euros, payable to Health Care Conference Administrators, LLC).


FAX: +1 206-319-5303 (include credit card information with registration)

MAIL: Conference Office, 12330 N.E. 8th Street, Suite 101, Bellevue, WA 98005-3187, USA

FOR REGISTRATION QUESTIONS:

PHONE: 1 800-503-8171 (Continental US, Alaska and Hawaii only) or +1 206-452-5528, Monday-Friday, 7 AM - 5 PM PST

E-MAIL: registration@hcconferences.com

CONTACT INFORMATION – INTERNATIONAL CALL CENTER:

LONDON, UK — The International Pharma Congress has engaged the UK firm of Bamboo Events Ltd. as agent to handle telephone and email enquiries.

Hours: 9:00 – 17:00 (UK time)  
Phone: +44 (0)208 407 6167

Email: IPCcallcenter@hcconferences.com

COMPLETE THE FOLLOWING. PLEASE PRINT CLEARLY:

NAME

SIGNATURE OF REGISTRANT - REQUIRED

JOB TITLE

ORGANIZATION

ADDRESS

CITY/STATE or PROVINCE/POSTAL CODE

COUNTRY

TELEPHONE

E-MAIL

☒ Special Needs (Dietary or Physical)

PAYMENT

The use of a registration discount code cannot be the basis of requesting a partial refund of fees already paid.

TOTAL FOR ALL OPTIONS:

Please enclose payment with your registration and return it to the Registrar at International Pharma Congress, 12330 N.E. 8th Street, Suite 101, Bellevue, WA 98005-3187, USA, or fax your credit card payment to 1-206-319-5303.

You may also register online at www.InternationalPharmaCongress.com.

☒ Bank transfer (bank information provided upon receipt of form)

☒ Payment by credit card: ☒ American Express ☒ Visa ☒ Mastercard

If a credit card number is being given to hold registration only until such time as a bank transfer is received it must be so noted. If payment is not received by seven days prior to the Congress, the credit card payment will be processed. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC.

ONLINE CONFERENCE ATTENDANCE

Onsite conference registration includes onsite attendance, professional networking, and live interaction with the faculty.

PRECONFERENCE:

☒ EFPIA Codes Training Workshop No Cost

CONFERENCE – Standard Individual Rate:

☒ Through Friday, March 10, 2017* €1,795

☒ Through Friday, April 14, 2017** €1,995

☒ After Friday, April 14, 2017 €2,195

CONFERENCE – Standard Group Rate:

Group registrations submitted from the same organization at the same time receive the following discounted rate for conference registration:

☒ Five or more (per person): €1,495

☒ Ten or more (per person): €1,395

ETHICS/PCF/IPFMA/EFPIA/PhRMAG Member Rate***:

☒ Through Friday, March 10, 2017* €1,395

☒ Through Friday, April 14, 2017** €1,595

☒ After Friday, April 14, 2017 €1,795

CONFERENCE – ETHICS/PCF/IPFMA/EFPIA/PhRMAG Group Rate***:

Group registrations submitted from the same organization at the same time receive the following discounted rate for conference registration:

☒ Five or more (per person): €1,295

☒ Ten or more (per person): €1,195

SELECT YOUR MINI-SUMMITS (One from each group):

ROUND I – Monday, May 15, 4:15 pm

☒ 1: Transparency: How can we leverage it to improve compliance?

☒ 2: Annual MEA Compliance Roundtable

☒ 3: Health Economics and Outcomes Research (HEOR) — Emerging Risks of Data Collection, Use, and Secondary Use

☒ 4: Evolving Privacy Requirements: Preparing for the General Data Protection Regulation

☒ 5: Managing Medical Device Anti-Corruption Risks

ROUND II – Tuesday, May 16, 11:15 am

☒ 6: Practical Implications of Brexit on Life Science Companies

☒ 7: The Interfaces between the Roles of the Compliance and Quality Functions

☒ 8: Risk Assessments and Monitoring Plans, Part I

☒ 9: Patient Programs and Interactions with Patient Organizations — Managing the Risks of Getting Closer to the Patient

☒ 10: Global Transparency Data Analytics: What they mean for your company

ROUND III – Tuesday, May 16, 4:30 pm

☒ 11: Next Generation Compliance: Fostering Decision-Making in a Principle-Based Compliance Program

☒ 12: Risk Assessment and Monitoring Plans, Part II

☒ 13: The Challenges of New Channels: Digital Communications, Social Media, and Other New Technologies

☒ 14: Advanced Topics in Anti-Corruption Compliance Programs

☒ 15: Impact of Self-Regulation Schemes on Industry Relationships with HCPS, HCOS and Patient Organizations

APPLICABLE VAT FOR ONSITE ATTENDANCE:

Upon registering to attend the Congress in-person onsite, you will be charged an additional 23% VAT tax. Upon receipt by the Congress of its Portuguese VAT number, you will be emailed a final invoice.

* This price reflects a discount for registration & payment received by March 10, 2017.

** This price reflects a discount for registration & payment received by April 14, 2017.

*** To qualify for the ETHICS/PCF/IPFMA/EFPIA/PhRMAG/OPPI/USIBC member rate an individual must be an individual member or an employee of a member company of the International Society of Healthcare Ethics and Compliance Professionals (ethics), the Pharmaceutical Compliance Forum (PCF), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), Pharmaceutical Research and Manufacturers Association, Gulf (PhRMAG) or the Organization of Pharmaceutical Producers of India (OPPI) or the US India Business Council (USIBC).